Last reviewed · How we verify
NCT04746313: SCLERO-PRL
Prevalence of Hyperprolactinemia in Systemic Scleroderma
trial testing blood test in Sclerosis, Systemic in 71 participants. Completed in 12 May 2021.
12 May 2021
Quick facts
| Lead sponsor | University Hospital, Lille |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 71 |
| Start date | 1 March 2021 |
| Primary completion | 12 May 2021 |
| Estimated completion | 12 May 2021 |
| Sites | 1 location across France |
Drugs / interventions tested
- blood test — full drug profile →
Conditions studied
- Sclerosis, Systemic — all drugs for Sclerosis, Systemic →
- Scleroderma — all drugs for Scleroderma →
- Hyperprolactinemia — all drugs for Hyperprolactinemia →
Sponsor
University Hospital, Lille
Who can join
18 and older, any sex, with Sclerosis, Systemic or Scleroderma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Systemic sclerosis is an autoimmune and inflammatory disease characterized primarily by fibrosis and vascular involvement. We know that the immune system is disrupted in systemic sclerosis, but there are probably other mechanisms to explain the disease, including deregulation of certain proteins such as prolactin
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04746313
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of blood test
Trials testing the same drug.
- NCT06971289 — Development and Characterization of Functional Assays for the Analysis of Inflammation Signaling Pathways · not yet recruiting
- NCT06983197 — Iatrogenic Deficiencies in ICU Patients With Prolonged Continuous Renal Replacement Therapy · not yet recruiting
- NCT06375889 — Platelet Activation in Delayed Cerebral Ischemia Secondary to Aneurysmal Subarachnoid Hemorrhage · completed
- NCT05901207 — Diagnostic and Prognostic Biomarkers for IgG4-related Disease. · unknown
- NCT06212505 — EVALUATION of the OVERALL HAEMOSTATIC CAPACITY of MIM8 with GLOBAL HAEMOSTASIS ASSAYS and FIBRIN CLOT ULTRASTRUCTURE · completed
Other University Hospital, Lille trials
Trials by the same sponsor.
- NCT07528664 — Assessement of a Test a Financial-incentive Program for Pregnant Women and Their Smoking Partners to Reduce Smoking Duri · NA · not yet recruiting
- NCT07434739 — PAravertebral CaTheter Versus Epidural Analgesia in Totally Minimally Invasive Esophagectomies · NA · not yet recruiting
- NCT06958224 — Theranostic Approach by Early Multigene Sequencing in Advanced Poor Prognosis Cancers · NA · not yet recruiting
- NCT07408999 — Totally Versus Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer · NA · not yet recruiting
- NCT07492030 — Validation of the Use of the Arteriovenous Tension Difference in CO2 Under Hyperbaric Conditions · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04746313 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Lille
- Last refreshed: 23 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04746313.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing